A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal

Pamela Rose Schroeder, Bryan R. Haugen, Furio Pacini, Christoph Reiners, Martin Schlumberger, Steven I. Sherman, David S Cooper, Kathryn G. Schuff, Lewis E. Braverman, Monica C. Skarulis, Terry F. Davies, Ernest L. Mazzaferri, Gilbert H. Daniels, Douglas S. Ross, Markus Luster, Mary H. Samuels, Bruce D. Weintraub, E. Chester Ridgway, Paul W Ladenson

Research output: Contribution to journalArticle

Abstract

Context: Thyroid carcinoma requires lifelong monitoring with serum thyroglobulin, radioactive iodine whole body scanning, and other imaging modalities. Levothyroxine (L-T4) withdrawal for thyroglobulin measurement and whole body scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal. Objective: Our objective was to examine the impact of short-term hypothyroidism on the health-related quality of life (HRQOL) of patients after rhTSH vs. L-T4 withdrawal. Design, Setting, and Patients: In this multicenter study, the SF-36 Health Survey was administered to 228 patients at three time points: on L-T4, after rhTSH, and after L-T4 withdrawal. Interventions: Interventions included administration of rhTSH on L-T4 and withdrawal from thyroid hormone. Main Outcome Measures: Mean SF-36 scores were compared during the two interventions and with the U.S. general population and patients with heart failure, depression, and migraine headache. Results: Patients had SF-36 scores at or above the norm for the general U.S. population in six of eight domains at baseline on L-T 4 and in seven of eight domains after rhTSH. Patients' scores declined significantly in all eight domains after L-T4 withdrawal when compared with the other two periods (P <0.0001). Patients' HRQOL scores while on L-T4 and after rhTSH were at or above those for patients with heart failure, depression, and migraine in all eight domains. After L-T4 withdrawal, patients' HRQOL scores were significantly below congestive heart failure, depression, and migraine headache norms in six, three, and six of the eight domains, respectively. Conclusions: Short-term hypothyroidism after L-T4 withdrawal is associated with a significant decline in quality of life that is abrogated by rhTSH use.

Original languageEnglish (US)
Pages (from-to)878-884
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Thyrotropin Alfa
Thyrotropin
Thyroid Hormones
Thyroid Neoplasms
Quality of Life
Health
Hypothyroidism
Migraine Disorders
Thyroglobulin
Whole Body Imaging
Thyroxine
Heart Failure
Scanning
Iodine
Health Surveys
Population
Multicenter Studies
Imaging techniques
Monitoring
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. / Schroeder, Pamela Rose; Haugen, Bryan R.; Pacini, Furio; Reiners, Christoph; Schlumberger, Martin; Sherman, Steven I.; Cooper, David S; Schuff, Kathryn G.; Braverman, Lewis E.; Skarulis, Monica C.; Davies, Terry F.; Mazzaferri, Ernest L.; Daniels, Gilbert H.; Ross, Douglas S.; Luster, Markus; Samuels, Mary H.; Weintraub, Bruce D.; Ridgway, E. Chester; Ladenson, Paul W.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 3, 03.2006, p. 878-884.

Research output: Contribution to journalArticle

Schroeder, PR, Haugen, BR, Pacini, F, Reiners, C, Schlumberger, M, Sherman, SI, Cooper, DS, Schuff, KG, Braverman, LE, Skarulis, MC, Davies, TF, Mazzaferri, EL, Daniels, GH, Ross, DS, Luster, M, Samuels, MH, Weintraub, BD, Ridgway, EC & Ladenson, PW 2006, 'A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal', Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, pp. 878-884. https://doi.org/10.1210/jc.2005-2064
Schroeder, Pamela Rose ; Haugen, Bryan R. ; Pacini, Furio ; Reiners, Christoph ; Schlumberger, Martin ; Sherman, Steven I. ; Cooper, David S ; Schuff, Kathryn G. ; Braverman, Lewis E. ; Skarulis, Monica C. ; Davies, Terry F. ; Mazzaferri, Ernest L. ; Daniels, Gilbert H. ; Ross, Douglas S. ; Luster, Markus ; Samuels, Mary H. ; Weintraub, Bruce D. ; Ridgway, E. Chester ; Ladenson, Paul W. / A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. In: Journal of Clinical Endocrinology and Metabolism. 2006 ; Vol. 91, No. 3. pp. 878-884.
@article{891e4ea299274a90aa19cc8315617f9d,
title = "A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal",
abstract = "Context: Thyroid carcinoma requires lifelong monitoring with serum thyroglobulin, radioactive iodine whole body scanning, and other imaging modalities. Levothyroxine (L-T4) withdrawal for thyroglobulin measurement and whole body scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal. Objective: Our objective was to examine the impact of short-term hypothyroidism on the health-related quality of life (HRQOL) of patients after rhTSH vs. L-T4 withdrawal. Design, Setting, and Patients: In this multicenter study, the SF-36 Health Survey was administered to 228 patients at three time points: on L-T4, after rhTSH, and after L-T4 withdrawal. Interventions: Interventions included administration of rhTSH on L-T4 and withdrawal from thyroid hormone. Main Outcome Measures: Mean SF-36 scores were compared during the two interventions and with the U.S. general population and patients with heart failure, depression, and migraine headache. Results: Patients had SF-36 scores at or above the norm for the general U.S. population in six of eight domains at baseline on L-T 4 and in seven of eight domains after rhTSH. Patients' scores declined significantly in all eight domains after L-T4 withdrawal when compared with the other two periods (P <0.0001). Patients' HRQOL scores while on L-T4 and after rhTSH were at or above those for patients with heart failure, depression, and migraine in all eight domains. After L-T4 withdrawal, patients' HRQOL scores were significantly below congestive heart failure, depression, and migraine headache norms in six, three, and six of the eight domains, respectively. Conclusions: Short-term hypothyroidism after L-T4 withdrawal is associated with a significant decline in quality of life that is abrogated by rhTSH use.",
author = "Schroeder, {Pamela Rose} and Haugen, {Bryan R.} and Furio Pacini and Christoph Reiners and Martin Schlumberger and Sherman, {Steven I.} and Cooper, {David S} and Schuff, {Kathryn G.} and Braverman, {Lewis E.} and Skarulis, {Monica C.} and Davies, {Terry F.} and Mazzaferri, {Ernest L.} and Daniels, {Gilbert H.} and Ross, {Douglas S.} and Markus Luster and Samuels, {Mary H.} and Weintraub, {Bruce D.} and Ridgway, {E. Chester} and Ladenson, {Paul W}",
year = "2006",
month = "3",
doi = "10.1210/jc.2005-2064",
language = "English (US)",
volume = "91",
pages = "878--884",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal

AU - Schroeder, Pamela Rose

AU - Haugen, Bryan R.

AU - Pacini, Furio

AU - Reiners, Christoph

AU - Schlumberger, Martin

AU - Sherman, Steven I.

AU - Cooper, David S

AU - Schuff, Kathryn G.

AU - Braverman, Lewis E.

AU - Skarulis, Monica C.

AU - Davies, Terry F.

AU - Mazzaferri, Ernest L.

AU - Daniels, Gilbert H.

AU - Ross, Douglas S.

AU - Luster, Markus

AU - Samuels, Mary H.

AU - Weintraub, Bruce D.

AU - Ridgway, E. Chester

AU - Ladenson, Paul W

PY - 2006/3

Y1 - 2006/3

N2 - Context: Thyroid carcinoma requires lifelong monitoring with serum thyroglobulin, radioactive iodine whole body scanning, and other imaging modalities. Levothyroxine (L-T4) withdrawal for thyroglobulin measurement and whole body scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal. Objective: Our objective was to examine the impact of short-term hypothyroidism on the health-related quality of life (HRQOL) of patients after rhTSH vs. L-T4 withdrawal. Design, Setting, and Patients: In this multicenter study, the SF-36 Health Survey was administered to 228 patients at three time points: on L-T4, after rhTSH, and after L-T4 withdrawal. Interventions: Interventions included administration of rhTSH on L-T4 and withdrawal from thyroid hormone. Main Outcome Measures: Mean SF-36 scores were compared during the two interventions and with the U.S. general population and patients with heart failure, depression, and migraine headache. Results: Patients had SF-36 scores at or above the norm for the general U.S. population in six of eight domains at baseline on L-T 4 and in seven of eight domains after rhTSH. Patients' scores declined significantly in all eight domains after L-T4 withdrawal when compared with the other two periods (P <0.0001). Patients' HRQOL scores while on L-T4 and after rhTSH were at or above those for patients with heart failure, depression, and migraine in all eight domains. After L-T4 withdrawal, patients' HRQOL scores were significantly below congestive heart failure, depression, and migraine headache norms in six, three, and six of the eight domains, respectively. Conclusions: Short-term hypothyroidism after L-T4 withdrawal is associated with a significant decline in quality of life that is abrogated by rhTSH use.

AB - Context: Thyroid carcinoma requires lifelong monitoring with serum thyroglobulin, radioactive iodine whole body scanning, and other imaging modalities. Levothyroxine (L-T4) withdrawal for thyroglobulin measurement and whole body scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal. Objective: Our objective was to examine the impact of short-term hypothyroidism on the health-related quality of life (HRQOL) of patients after rhTSH vs. L-T4 withdrawal. Design, Setting, and Patients: In this multicenter study, the SF-36 Health Survey was administered to 228 patients at three time points: on L-T4, after rhTSH, and after L-T4 withdrawal. Interventions: Interventions included administration of rhTSH on L-T4 and withdrawal from thyroid hormone. Main Outcome Measures: Mean SF-36 scores were compared during the two interventions and with the U.S. general population and patients with heart failure, depression, and migraine headache. Results: Patients had SF-36 scores at or above the norm for the general U.S. population in six of eight domains at baseline on L-T 4 and in seven of eight domains after rhTSH. Patients' scores declined significantly in all eight domains after L-T4 withdrawal when compared with the other two periods (P <0.0001). Patients' HRQOL scores while on L-T4 and after rhTSH were at or above those for patients with heart failure, depression, and migraine in all eight domains. After L-T4 withdrawal, patients' HRQOL scores were significantly below congestive heart failure, depression, and migraine headache norms in six, three, and six of the eight domains, respectively. Conclusions: Short-term hypothyroidism after L-T4 withdrawal is associated with a significant decline in quality of life that is abrogated by rhTSH use.

UR - http://www.scopus.com/inward/record.url?scp=33644824080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644824080&partnerID=8YFLogxK

U2 - 10.1210/jc.2005-2064

DO - 10.1210/jc.2005-2064

M3 - Article

C2 - 16394083

AN - SCOPUS:33644824080

VL - 91

SP - 878

EP - 884

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -